Advertisement


Guru Sonpavde, MD, on Prostate Cancer: Targeting DNA Alterations

2017 Genitourinary Cancers Symposium

Advertisement

Guru Sonpavde, MD, of the UAB Comprehensive Cancer Center, discusses his study on circulating tumor DNA alterations in metastatic castration-resistant prostate cancer and the therapeutic direction the data suggest. (Abstract 149)



Related Videos

Prostate Cancer

Joshua Armenia, PhD, on Prostate Cancer: Recent Discoveries

Joshua Armenia, PhD, of Memorial Sloan Kettering Cancer Center, discusses new information that is changing the understanding of prostate cancer, including the identification of a new subclass, which represents 21% of cases, and the discovery of recurrently mutated cancer pathways not previously implicated in prostate cancer (Abstract 131).

Prostate Cancer

Paul L. Nguyen, MD, on Prostate Cancer: Active Surveillance

Paul L. Nguyen, MD, of the Dana-Farber Cancer Institute, summarizes a session he co-chaired, which included discussion of Canadian vs U.S. guidelines; ProtecT; genomic and hereditary tests; and imaging to guide active surveillance. (General Session 1)

Bladder Cancer

Karim Chamie, MD, on Bladder Cancer: Optimizing Surgical and Medical Therapies

Karim Chamie, MD, of the University of California, Los Angeles, discusses induction and maintenance BCG therapy in non–muscle-invasive bladder cancer.

Kidney Cancer

Rana R. McKay, MD, on RCC: Continuing Benefit After Halting Treatment

Rana R. McKay, MD, of the University of California, San Diego, discusses study findings on PD-1/PD-L1 responders with metastatic renal cell carcinoma who discontinue therapy for immune-related adverse events. (Abstract 467)

Kidney Cancer

Sumanta K. Pal, MD, on RCC and Tumor Profiling

Sumanta K. Pal, MD, of the City of Hope, discusses the evolution of circulating tumor DNA profile from first-line to second-line therapy in metastatic renal cell carcinoma. (Abstract 434)

Advertisement

Advertisement




Advertisement